In this melanoma pre-clinical model, Tyr:CreER:BrafCA:Ptenlox/lox (BRAF/PTEN), topical application of 4-hydroxytamoxifen (4-HT) to the skin induces an active Braf V600E mutation and Pten deletion in melanocytes [34, 35]. Here, BRAF is linked to melanoma.